Large Molecule Capabilities Overview: Large CDMO Strength, Small CDMO Agility

Rose Romberg, Senior Director of Business Development at Cytovance Biologics, offers a detailed look at how the organization approaches large molecule development and manufacturing in today’s competitive CDMO landscape. Framed by the idea of “large CDMO strength, small CDMO agility,” she explains how two decades of experience underpin a development model built on responsiveness, technical depth, and close client collaboration.

Romberg highlights Cytovance’s integrated support for both mammalian and microbial programs, covering early development through commercial-scale production. She also points to the company’s high batch success rates, seasoned technical teams, and strong regulatory track record — factors that help ensure continuity and confidence for partners advancing complex biologics.

With operations based in Oklahoma, the organization benefits from a central U.S. location and an expanding regional commitment to biotech infrastructure. Romberg also explores how the team adapts to accelerating timelines, cost pressures, and evolving regulatory expectations while maintaining quality and flexibility.

Together, these elements position Cytovance as a capable, agile partner for programs progressing from concept to commercialization.